编辑“︁NNC 45-0095”︁

{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 4-(1-ethylpyrrolo[2,1,5-''cd'']indolizin-2-yl)phenol
| image = NNC 45-0095.svg
| width = 

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
| class = [[選擇性雌激素受體調節物]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 217318-90-6
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9903336
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 8078990
| UNII = IS4M82C29X
| KEGG = 
| ChEBI = 
| ChEMBL = 420017
| synonyms = NNC-450095

<!--Chemical data-->
| C=18 | H=15 | N=1 | O=1
| SMILES = CCC1=C(C2=CC=C3N2C1=CC=C3)C4=CC=C(C=C4)O
| StdInChI_Ref = 
| StdInChI = 1S/C18H15NO/c1-2-15-16-5-3-4-13-8-11-17(19(13)16)18(15)12-6-9-14(20)10-7-12/h3-11,20H,2H2,1H3
| StdInChIKey_Ref = 
| StdInChIKey = GBHFDPQPLXKNIU-UHFFFAOYSA-N
}}
'''{{PAGENAME}}'''是一种含氮[[有机化合物]]，化学式[[C18H17NO|C<sub>18</sub>H<sub>17</sub>NO]]，可作为[[非甾体]][[選擇性雌激素受體調節物]]（SERMs），由[[诺和诺德]]开发，用于治疗[[骨質疏鬆症]]，从未上市销售。<ref name="pmid10714509">{{cite journal | vauthors = Jørgensen AS, Jacobsen P, Christiansen LB, Bury PS, Kanstrup A, Thorpe SM, Bain S, Naerum L, Wassermann K | display-authors = 6 | title = Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor | journal = Bioorganic & Medicinal Chemistry Letters | volume = 10 | issue = 4 | pages = 399–402 | date = February 2000 | pmid = 10714509 | doi = 10.1016/S0960-894X(00)00015-9 }}</ref><ref name="SharmaKumar2014">{{cite journal| vauthors = Sharma V, Kumar V |title=Indolizine: a biologically active moiety|journal=Medicinal Chemistry Research|volume=23|issue=8|year=2014|pages=3593–3606|issn=1054-2523|doi=10.1007/s00044-014-0940-1|s2cid=2643469}}</ref><ref name="pmid14683521">{{cite journal | vauthors = Wallace OB, Richardson TI, Dodge JA | title = Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity | journal = Current Topics in Medicinal Chemistry | volume = 3 | issue = 14 | pages = 1663–1682 | date = 2003 | pmid = 14683521 | doi = 10.2174/1568026033451727 }}</ref><ref name="RahmanReitz2010">{{cite book | vauthors = Meegan MJ, Lloyd DG | chapter = Understanding the Molecular Mechanism of Action of Estrogen Receptor Modulators. Frontiers in Medicinal Chemistry-Online | date = January 2005 | volume = 2 | issue = 1 | pages = 183-231 (206) | veditors = Atta-ur-Rahman, Reitz AB |title=Frontiers in Medicinal Chemistry|chapter-url=https://books.google.com/books?id=tCyDoIHToBQC&pg=PA206 |publisher=Bentham Science Publishers|isbn=978-1-60805-205-9 }}</ref><ref name="AdisInsight">{{Cite web | url = https://adisinsight.springer.com/drugs/800014610 | title = NNC 450095 | work = AdisInsight | publisher = Springer Nature Switzerland AG | access-date = 2024-01-18 | archive-date = 2024-01-18 | archive-url = https://web.archive.org/web/20240118052507/https://adisinsight.springer.com/drugs/800014610 | dead-url = no }}</ref>

==参考文献==
{{reflist|30em}}

[[Category:中止研发的药物]]
[[Category:中氮茚]]
[[Category:对羟苯基化合物]]
[[Category:選擇性雌激素受體調節劑]]